Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(09): 596-603
DOI: 10.1055/a-1713-7719
Article

Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells

Zhihong Zhou   *
1   Department of Geriatrics, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou City, Hainan Province, China
,
Shangjun Liu   *
2   Department of Cardiovascular Medicine, Sanya Central Hospital (Hainan Third People’s Hospital), Sanya City, Hainan Province, China
› Author Affiliations Funding This study was funded by the “Hainan Provincial Natural Science Foundation of China (Grant No.20158294)”.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Maprotiline is an antidepressant that has been found to cause hypoglycemia. However, the effect of maprotiline on diabetic nephropathy (DN) has not been investigated. Here, we explored the effect of maprotiline on human renal glomerular endothelial cells (HRGECs) in response to high glucose (HG) stimulation. We found that maprotiline attenuated HG-induced oxidative stress in HRGECs with decreased reactive oxygen species production and increased superoxide dismutase activity. Maprotiline repressed the HG-induced expression of cyclooxygenases 2 at both mRNA and protein levels in HRGECs. The increased thromboxane B2 level and decreased 6-keto-prostaglandin F1α level induced by HG were significantly attenuated by maprotiline treatment. Maprotiline also prevented the HG-induced increase in the permeability of HRGECs and the decrease in the zonula occludens-1 expression and downregulated HG-induced increase in the expression of protein kinase C-α (PKC-α) in HRGECs. This protective effect of maprotiline on HG-induced HRGECs dysfunction was abolished by overexpression of PKC-α. In conclusion, maprotiline displayed a protective effect on HG-challenged HRGECs, which was mediated by the regulation of PKC-α. These findings provide further evidence for the potential use of maprotiline for the treatment of DN.

Key words

Maprotiline - diabetic nephropathy (DN) - oxidative stress - inflammation - permeability - protein kinase C (PKC)

* Contributed equally to this work




Publication History

Received: 13 August 2021
Received: 03 November 2021

Accepted: 30 November 2021

Article published online:
23 March 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lu Y, Liu D, Feng Q. et al. Diabetic nephropathy: Perspective on extracellular vesicles. Front Immunol 2020; 11: 943
    CrossrefPubMedGoogle Scholar
  • 2 Zheng S, Powell DW, Zheng F. et al. Diabetic nephropathy: Proteinuria, inflammation, and fibrosis. J Diabetes Res 2016; 2016: 5241549
    PubMedGoogle Scholar
  • 3 Tonneijck L, Muskiet MH, Smits MM. et al. Glomerular hyperfiltration in diabetes: Mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017; 28: 1023-1039
    CrossrefPubMedGoogle Scholar
  • 4 Sagoo MK, Gnudi L. Diabetic nephropathy: An overview. Methods Mol Biol 2020; 2067: 3-7
    Google Scholar
  • 5 Daehn IS, Duffield JS. The glomerular filtration barrier: A structural target for novel kidney therapies. Nat Rev Drug Discov 2021; 1-19
    PubMedGoogle Scholar
  • 6 Ebefors K, Lassen E, Anandakrishnan N. et al. Modeling the glomerular filtration barrier and intercellular crosstalk. Front Physiol 2021; 12: 689083
    CrossrefPubMedGoogle Scholar
  • 7 Chen SJ, Lv LL, Liu BC. et al. Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease. Cell Prolif 2020; 53: e12763
    PubMedGoogle Scholar
  • 8 Fu J, Lee K, Chuang PY. et al. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol 2015; 308: F287-F297
    CrossrefPubMedGoogle Scholar
  • 9 Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013; 124: 139-152
    CrossrefPubMedGoogle Scholar
  • 10 Donate-Correa J, Luis-Rodriguez D, Martin-Nunez E. et al. Inflammatory targets in diabetic nephropathy. J Clin Med 2020; 9: 458
    CrossrefPubMedGoogle Scholar
  • 11 Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Res Clin Pract 2008; 79: 61-67
    CrossrefPubMedGoogle Scholar
  • 12 Andersohn F, Schade R, Suissa S. et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-598
    CrossrefPubMedGoogle Scholar
  • 13 Atlantis E, Browning C, Sims J. et al. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010; 25: 688-696
    CrossrefPubMedGoogle Scholar
  • 14 Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011; 33: 484-492
    CrossrefPubMedGoogle Scholar
  • 15 Parra A, Martos A, Monleon S. et al. Effects of acute and chronic maprotiline administration on inhibitory avoidance in male mice. Behav Brain Res 2000; 109: 1-7
    CrossrefPubMedGoogle Scholar
  • 16 Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999; 22: 862-863
    CrossrefPubMedGoogle Scholar
  • 17 Zogno MG, Tolfo L, Draghi E. Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics. Ann Pharmacother 1994; 28: 406
    CrossrefPubMedGoogle Scholar
  • 18 Chen YC, Shen YC, Hung YJ. et al. Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. J Affect Disord 2007; 103: 257-261
    CrossrefPubMedGoogle Scholar
  • 19 Pinar M, Gulsun M, Tasci I. et al. Maprotiline induced weight gain in depressive disorder: Changes in circulating ghrelin and adiponectin levels and insulin sensitivity. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 135-139
    CrossrefPubMedGoogle Scholar
  • 20 Lee WC, Chau YY, Ng HY. et al. Empagliflozin protects HK-2 cells from high glucose-mediated injuries via a mitochondrial mechanism. Cells 2019; 8: 1085 DOI: 10.3390/cells8091085.
    CrossrefPubMedGoogle Scholar
  • 21 Rafiee L, Hajhashemi V, Javanmard SH. Maprotiline inhibits LPS-induced expression of adhesion molecules (ICAM-1 and VCAM-1) in human endothelial cells. Res Pharm Sci 2016; 11: 138-144
    PubMedGoogle Scholar
  • 22 Gao F, Zhang S. Loratadine alleviates advanced glycation end product-induced activation of NLRP3 inflammasome in human chondrocytes. Drug Des Devel Ther 2020; 14: 2899-2908
    CrossrefPubMedGoogle Scholar
  • 23 Liu X, Wang B, Ding H. et al. Low-intensity pulsed ultrasound in combination with SonoVue induces cytotoxicity of human renal glomerular endothelial cells via repression of the ERK1/2 signaling pathway. Ren Fail 2018; 40: 458-465
    CrossrefPubMedGoogle Scholar
  • 24 Kalani A, Kamat PK, Chaturvedi P. et al. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci 2014; 107: 1-7
    CrossrefPubMedGoogle Scholar
  • 25 Dowlati Y, Herrmann N, Swardfager W. et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457
    CrossrefPubMedGoogle Scholar
  • 26 Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav 1994; 48: 845-851
    CrossrefPubMedGoogle Scholar
  • 27 Maes M, Song C, Lin AH. et al. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 370-379
    CrossrefPubMedGoogle Scholar
  • 28 Rafiee L, Hajhashemi V, Javanmard SH. Maprotiline inhibits COX2 and iNOS gene expression in lipopolysaccharide-stimulated U937 macrophages and carrageenan-induced paw edema in rats. Cent Eur J Immunol 2019; 44: 15-22
    CrossrefPubMedGoogle Scholar
  • 29 Sadeghi H, Hajhashemi V, Minaiyan M. et al. Further studies on anti-inflammatory activity of maprotiline in carrageenan-induced paw edema in rat. Int Immunopharmacol 2013; 15: 505-510
    CrossrefPubMedGoogle Scholar
  • 30 Kruger-Genge A, Blocki A, Franke RP. et al. Vascular endothelial cell biology: An update. Int J Mol Sci 2019; 20: 4411
    PubMedGoogle Scholar
  • 31 Sakai K, Ito K, Ogawa K. Roles of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart. J Cardiovasc Pharmacol 1982; 4: 129-135
    CrossrefPubMedGoogle Scholar
  • 32 Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978; 30: 293-331
    PubMedGoogle Scholar
  • 33 Zhang J, Feng Y, Li S. et al. Microvascular pathological features and changes in related injury factors in a rat acute blood stasis model. J Tradit Chin Med 2017; 37: 108-115
    CrossrefPubMedGoogle Scholar
  • 34 Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin 2019; 40: 1-8
    CrossrefPubMedGoogle Scholar
  • 35 Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-1331
    CrossrefPubMedGoogle Scholar
  • 36 Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88: 1341-1378
    CrossrefPubMedGoogle Scholar
  • 37 Haller H. Postprandial glucose and vascular disease. Diabet Med 1997; 14: S50-S56
    CrossrefPubMedGoogle Scholar
  • 38 Lynch JJ, Ferro TJ, Blumenstock FA. et al. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest 1990; 85: 1991-1998
    CrossrefPubMedGoogle Scholar